Evicenter
MarkdownMedical informationP&T meetings
Darovasertib (IDE196)

First-line metastatic uveal melanoma, in combination with crizotinib

Also known as LXS196
Manufacturer
IDEAYA Biosciences
Launch
Not announced
Last updated
206 sources

Executive summary

Budget impact of Darovasertib

1 evidence topic · 8 sources

Summary

No price, wholesale acquisition cost, budget impact model, or cost-effectiveness analysis of darovasertib or of the darovasertib plus crizotinib regimen was found. In OptimUM-02, darovasertib 300 mg twice daily is given with crizotinib 200 mg twice daily; Pfizer lists the wholesale acquisition cost of XALKORI at $23,773.10 per package of 60 capsules for both the 200 mg and 250 mg strengths, accurate as of March 10, 2026. IDEAYA states that darovasertib, if approved for one or more designated indications, “may also be excluded from certain mandatory price negotiation provisions of the 2022 Inflation Reduction Act”. Median duration of treatment in OptimUM-02 was 6.31 months for darovasertib and crizotinib, against 2.87, 2.56, and 2.79 months for pembrolizumab, ipilimumab, and nivolumab in the control arm. Pembrolizumab is listed at $12,517.44 per dose given every 3 weeks (current as of September 2026), and tebentafusp (KIMMTRAK) at $22,050.00 per 100 mcg/0.5 mL vial (effective 1 July 2026). IDEAYA estimates approximately 1,500 newly diagnosed patients with metastatic uveal melanoma each year in the United States, and that HLA∗A2(-) patients represent “between 60-65% of all mUM patients”; other sources put HLA-A∗02:01-negative disease at 49% of individuals prescreened for a trial of tebentafusp and 42.9% of a U.S. real-world cohort.